Denis Larsimont
Overview
Explore the profile of Denis Larsimont including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
152
Citations
7625
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang X, Venet D, Lifrange F, Larsimont D, Rediti M, Stenbeck L, et al.
Nat Commun
. 2024 Nov;
15(1):10232.
PMID: 39592577
While triple-negative breast cancer (TNBC) is known to be heterogeneous at the genomic and transcriptomic levels, spatial information on tumor organization and cell composition is still lacking. Here, we investigate...
2.
Rediti M, Fimereli D, Mileva M, Wimana Z, Venet D, Flamen P, et al.
Clin Cancer Res
. 2024 Oct;
31(1):110-121.
PMID: 39470686
Purpose: The ZEPHIR clinical trial evaluated the role of [89Zr]trastuzumab-PET/CT (HER2-PET/CT) and 2-[18F]fluoro-2-deoxy-D-glucose PET/CT ([18F]FDG-PET/CT) in predicting outcomes in patients with advanced HER2-positive breast cancer treated with trastuzumab emtansine (T-DM1)....
3.
Leduc S, Nguyen H, Richard F, Zels G, Mahdami A, De Schepper M, et al.
Clin Exp Metastasis
. 2024 Mar;
41(5):699-705.
PMID: 38548918
Metastatic breast cancer (mBC) remains incurable and liver metastases (LM) are observed in approximately 50% of all patients with mBC. In some cases, surgical resection of breast cancer liver metastases...
4.
Jahangir C, Page D, Broeckx G, Gonzalez C, Burke C, Murphy C, et al.
J Pathol
. 2024 Jan;
262(3):271-288.
PMID: 38230434
Recent advances in the field of immuno-oncology have brought transformative changes in the management of cancer patients. The immune profile of tumours has been found to have key value in...
5.
Pop C, Veys I, Bormans A, Larsimont D, Liberale G
Breast Cancer Res Treat
. 2024 Jan;
204(3):429-442.
PMID: 38182824
Background: This review summarizes the available data on the effectiveness of indocyanine green fluorescence imaging (ICG-FI) for real-time detection of breast cancer (BC) tumors with perioperative imaging technologies. Methods: PubMed...
6.
De Schepper M, Nguyen H, Richard F, Rosias L, Lerebours F, Vion R, et al.
Cancer Res Commun
. 2023 Dec;
4(1):186-199.
PMID: 38147006
Significance: IBC is a rare, but very aggressive type of breast cancer. The prognostic role of pCR after systemic therapy and the predictive value of sTILs for pCR are well...
7.
Leduc S, De Schepper M, Richard F, Maetens M, Pabba A, Borremans K, et al.
NPJ Breast Cancer
. 2023 Dec;
9(1):100.
PMID: 38102162
Liver is the third most common organ for breast cancer (BC) metastasis. Two main histopathological growth patterns (HGP) exist in liver metastases (LM): desmoplastic and replacement. Although a reduced immunotherapy...
8.
Buisseret L, Loirat D, Aftimos P, Maurer C, Punie K, Debien V, et al.
Nat Commun
. 2023 Dec;
14(1):8223.
PMID: 38086864
No abstract available.
9.
De Caluwe A, Romano E, Poortmans P, Gombos A, Agostinetto E, Marta G, et al.
J Immunother Cancer
. 2023 Dec;
11(12).
PMID: 38056900
Background: Luminal B breast cancer (BC) presents a worse prognosis when compared with luminal A BC and exhibits a lower sensitivity to chemotherapy and a lower immunogenicity in contrast to...
10.
Bohlok A, Richard F, Lucidi V, El Asmar A, Demetter P, Craciun L, et al.
Front Oncol
. 2023 Nov;
13:1260880.
PMID: 37965465
Surgical resection can lead to prolonged survival in patients with isolated liver metastases (LM) from various primary cancers. However, there are currently no validated predictive markers to discriminate between these...